Exchange Traded Concepts LLC Has $157,000 Stock Position in Kura Oncology, Inc. (NASDAQ:KURA)

Exchange Traded Concepts LLC reduced its position in shares of Kura Oncology, Inc. (NASDAQ:KURA) by 18.9% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 8,024 shares of the company’s stock after selling 1,864 shares during the quarter. Exchange Traded Concepts LLC’s holdings in Kura Oncology were worth $157,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. raised its stake in shares of Kura Oncology by 0.7% in the first quarter. Vanguard Group Inc. now owns 4,065,903 shares of the company’s stock worth $86,726,000 after purchasing an additional 28,212 shares during the last quarter. Avoro Capital Advisors LLC raised its position in Kura Oncology by 29.2% in the 1st quarter. Avoro Capital Advisors LLC now owns 3,850,000 shares of the company’s stock valued at $82,120,000 after buying an additional 870,000 shares during the last quarter. Armistice Capital LLC raised its position in Kura Oncology by 14.7% in the 2nd quarter. Armistice Capital LLC now owns 2,350,000 shares of the company’s stock valued at $48,386,000 after buying an additional 302,000 shares during the last quarter. Artal Group S.A. boosted its holdings in Kura Oncology by 8.6% during the 1st quarter. Artal Group S.A. now owns 1,919,884 shares of the company’s stock worth $40,951,000 after acquiring an additional 151,828 shares during the last quarter. Finally, Assenagon Asset Management S.A. boosted its holdings in Kura Oncology by 50.1% during the 2nd quarter. Assenagon Asset Management S.A. now owns 1,731,577 shares of the company’s stock worth $35,653,000 after acquiring an additional 577,732 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on KURA shares. JMP Securities reaffirmed a “market outperform” rating and set a $32.00 price objective on shares of Kura Oncology in a report on Monday, August 12th. StockNews.com downgraded shares of Kura Oncology from a “hold” rating to a “sell” rating in a report on Thursday, August 22nd. Wedbush reaffirmed an “outperform” rating and set a $37.00 price objective on shares of Kura Oncology in a report on Friday, August 9th. Stifel Nicolaus downgraded shares of Kura Oncology from a “buy” rating to a “hold” rating and cut their price objective for the stock from $26.00 to $19.00 in a report on Monday, October 14th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Kura Oncology in a report on Monday, September 9th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, Kura Oncology presently has a consensus rating of “Moderate Buy” and a consensus target price of $29.20.

Kura Oncology Trading Down 1.7 %

NASDAQ KURA opened at $17.70 on Tuesday. The stock has a market capitalization of $1.35 billion, a price-to-earnings ratio of -8.16 and a beta of 0.84. Kura Oncology, Inc. has a one year low of $7.41 and a one year high of $24.17. The company has a debt-to-equity ratio of 0.02, a current ratio of 14.94 and a quick ratio of 14.94. The business’s fifty day moving average is $19.49 and its 200-day moving average is $20.17.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings data on Thursday, August 8th. The company reported ($0.59) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.04. During the same period in the prior year, the firm earned ($0.53) earnings per share. The business’s revenue was up .0% on a year-over-year basis. Equities research analysts predict that Kura Oncology, Inc. will post -2.45 EPS for the current year.

Kura Oncology Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.